A Drug Study on

GEMCITABINE

____________________

A Drug Study Presented to

the Faculty of Nursing Department
MARC JADE C. ALDAWAN, RN

____________________

In Partial Fulfillment of
the Requirements in NCM – 212 RLE
IMMUNOLOGY/CANCER ROTATION

By:

Kate Jannine S. Dela Cruz, ST.N.

BSN – 3F – Group 1 Subgroup 1

September 2022
 Genetic Name AMINOLIBEN
Brand Name
Classification Nutritional product
Mode of Action To normalize amino acids, carbohydrates, fats, vitamins
and minerals into plasma
Dosage/Route Adults: The usual dose is 500-1000 ml of Aminoleban
solution per intravenous infusion. Peripheral venous
infusion rate is 1.7-2.7 ml/min.

Total dose used for parenteral nutrition: 500-1000 ml in

combination with Dextrose or another compatible solution
infused through a central vein over 24 hours.

Dosage is adjusted for symptoms, age and weight.

Indications Prevention and treatment of hepatic encephalopathy in
patients with chronic liver failure, intravenous nutrition in
liver disease with or without hepatic encephalopathy,
correction of amino acid imbalance due to liver failure.
Contraindicatio Patients with serious renal disorder (patients on dialysis or
n hemofiltration are excluded). [Urea and other amino acid
metabolites may be retained, which may worsen the
patient's clinical condition.]

Patients with abnormal amino acid metabolism [Because

the infused amino acids are not adequately metabolized,
the patient's clinical condition may be worsened.]
Side Effect Diarrhea, headache, vomiting, nausea, chest pain, and
palpations, occasional chills, fever, and skin erruptions
Adverse Effect Hypoglycemia, hyperammonemia
Drug Interaction Ampicillinesters, ironderivatives, ketoronazole: may cause
poor bioavailability of the drugs; they need a low gastric Ph
 for optimal absorption.
Nursing
Responsibilities
https://www.scribd.com/document/339730676/Aminoleban#

https://www.scribd.com/doc/237008874/Aminoleban-Drug-Study